SYNGAP1 and neurodevelopmental disorder: Based on our previous success in other neurodevelopmental disorders including AS and SYNGAP1 using modified forms of their respective therapeutic proteins, we employed a similar strategy when developing the therapeutic MECP2 expressing lentiviral vector (Adhikari A. et al., 2021; Anderson JS.